Millipore Sigma Vibrant Logo
Attention: We have moved. Merck Millipore products are no longer available for purchase on MerckMillipore.com.Learn More

AB5336P Anti-Synuclein α Antibody

AB5336P
50 µg  
Purchase on Sigma-Aldrich

Különleges ajánlatok

Áttekintés

Replacement Information

Különleges ajánlatok

Kulcsspecifikációk táblázata

Species ReactivityKey ApplicationsHostFormatAntibody Type
H, M, RIH(P)ShAffinity PurifiedPolyclonal Antibody
Description
Catalogue NumberAB5336P
Replaces04-1053
Brand Family Chemicon®
Trade Name
  • Chemicon
DescriptionAnti-Synuclein α Antibody
References
Product Information
FormatAffinity Purified
PresentationAffinity purified immunoglobulin. Lyophilized. Reconstitute with 50 μL of sterile distilled water. Centrifuge to remove any residue. Glycerol (1:1) can be added for additional stability.
Quality LevelMQ100
Applications
ApplicationAnti-Synuclein Antibody, α is an antibody against Synuclein for use in IH(P).
Key Applications
  • Immunohistochemistry (Paraffin)
Application NotesImmunohistochemistry: 1:1,000 on frozen or paraffin sections.

Optimal working dilutions must be determined by the end user.
Biological Information
ImmunogenSynthetic peptide corresponding amino acids 108-120 of human alpha synuclein.
HostSheep
SpecificityRecognizes alpha synuclein.
Species Reactivity
  • Human
  • Mouse
  • Rat
Antibody TypePolyclonal Antibody
Entrez Gene Number
Entrez Gene SummaryAlpha-synuclein is a member of the synuclein family, which also includes beta- and gamma-synuclein. Synucleins are abundantly expressed in the brain and alpha- and beta-synuclein inhibit phospholipase D2 selectively. SNCA may serve to integrate presynaptic signaling and membrane trafficking. Defects in SNCA have been implicated in the pathogenesis of Parkinson disease. SNCA peptides are a major component of amyloid plaques in the brains of patients with Alzheimer's disease. Two alternatively spliced transcripts of SNCA have been identified. Additional splicing may be present but the full-length nature of these variants has not been determined.
Gene Symbol
  • SNCA
  • PD1
  • alpha-synuclein
  • NACP
  • PARK4
  • MGC110988
  • PARK1
  • Alpha-synuclein
UniProt Number
UniProt SummaryFUNCTION: SwissProt: P37840 # May be involved in the regulation of dopamine release and transport. Soluble protein, normally localized primarily at the presynaptic region of axons, which can form filamentous aggregates that are the major non amyloid component of intracellular inclusions in several neurodegenerative diseases (synucleinopathies). Induces fibrillization of microtubule- associated protein tau. Reduces neuronal responsiveness to various apoptotic stimuli, leading to a decreased caspase 3 activation.
SIZE: 140 amino acids; 14460 Da
SUBUNIT: Soluble monomer which can form filamentous aggregates. Interacts with UCHL1 (By similarity). Interacts with phospholipase D and histones.
SUBCELLULAR LOCATION: Cytoplasm. Membrane. Nucleus. Note=Membrane- bound in dopaminergic neurons. Also found in the nucleus.
TISSUE SPECIFICITY: Expressed principally in brain but is also expressed in low concentrations in all tissues examined except in liver. Concentrated in presynaptic nerve terminals.
DOMAIN: SwissProt: P37840 The NAC domain is involved in the fibril formation. The middle region forms the core of the filaments. The C-terminus may regulate aggregation and determine the diameter of the filaments.
PTM: Phosphorylated, predominantly on serine residues. Phosphorylation by CK1 appears to occur on residues distinct from the residue phosphorylated by other kinases. Phosphorylation of Ser-129 is selective and extensive in synucleinopathy lesions. In vitro, phosphorylation at Ser-129 promoted insoluble fibril formation. Phosphorylated on Tyr-125 by a PTK2B-dependent pathway upon osmotic stress. & Hallmark lesions of neurodegenerative synucleinopathies contain alpha-synuclein that is modified by nitration of tyrosine residues and possibly by dityrosine cross-linking to generated stable oligomers. & Ubiquitinated. The predominant conjugate is the diubiquitinated form (By similarity).
DISEASE: SwissProt: P37840 # Defects in SNCA are a cause of autosomal dominant Parkinson disease 1 (PARK1) [MIM:168601, 168600]. Parkinson disease (PD) is a complex, multifactorial disorder that typically manifests after the age of 50 years, although early-onset cases (before 50 years) are known. PD generally arises as a sporadic condition but is occasionally inherited as a simple mendelian trait. Although sporadic and familial PD are very similar, inherited forms of the disease usually begin at earlier ages and are associated with atypical clinical features. PD is characterized by bradykinesia, resting tremor, muscular rigidity and postural instability, as well as by a clinically significant response to treatment with levodopa. The pathology involves the loss of dopaminergic neurons in the substantia nigra and the presence of Lewy bodies (intraneuronal accumulations of aggregated proteins), in surviving neurons in various areas of the brain. & Defects in SNCA are the cause of Parkinson disease 4 (PARK4) [MIM:605543, 168600]. & Defects in SNCA are the cause of Lewy body dementia (DLB) [MIM:127750]. DLB is a neurodegenerative disorder clinically characterized by dementia and parkinsonism, often with fluctuating cognitive function, visual hallucinations, falls, syncopal episodes, and sensitivity to neuroleptic medication. Presence of Lewy bodies are the only essential pathologic features. & Deposition of fibrillar amyloid proteins intraneuronally as neurofibrillary tangles is characteristic of Alzheimer disease (AD). SNCA is a minor protein found within these deposits, but a major non amyloid component. & Brain iron accumulation type 1 (NBIA1, also called Hallervorden-Spatz syndrome), a rare neuroaxonal dystrophy, is histologically characterized by axonal spheroids, iron deposition, Lewy body (LB)-like intraneuronal inclusions, glial inclusions and neurofibrillary tangles. SNCA is found in LB-like inclusions, glial inclusions and spheroids.
SIMILARITY: Belongs to the synuclein family.
Physicochemical Information
Dimensions
Materials Information
Toxicological Information
Safety Information according to GHS
Safety Information
Product Usage Statements
Usage Statement
  • Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Storage and Shipping Information
Storage ConditionsMaintain lyophilized material at -70°C (dry) for up to 12 months. After reconstitution maintain at -20°C in undiluted aliquots for up to 6 months. Avoid repeated freeze/thaw cycles.
Packaging Information
Material Size50 µg
Transport Information
Supplemental Information
Specifications
Global Trade Item Number
Katalógusszám GTIN
AB5336P 04053252337574

Documentation

Anti-Synuclein α Antibody MSDS

Title

Safety Data Sheet (SDS) 

Anti-Synuclein α Antibody Certificates of Analysis

TitleLot Number
SHEEP ANTI-ALPHA SYNUCLEIN AFFINITY PURIFIED POLYCLONAL ANTIBODY - 2115530 2115530
SHEEP ANTI-ALPHA SYNUCLEIN - 3398586 3398586
SHEEP ANTI-ALPHA SYNUCLEIN -2519334 2519334
SHEEP ANTI-ALPHA SYNUCLEIN -2716593 2716593
SHEEP ANTI-ALPHA SYNUCLEIN -2741590 2741590
SHEEP ANTI-ALPHA SYNUCLEIN -2752719 2752719
SHEEP ANTI-ALPHA SYNUCLEIN -2804761 2804761
SHEEP ANTI-ALPHA SYNUCLEIN -2809302 2809302
SHEEP ANTI-ALPHA SYNUCLEIN -2891892 2891892
SHEEP ANTI-ALPHA SYNUCLEIN AFFINITY PURIFIED - 3026681 3026681

References

Reference overviewPub Med ID
Long-term consequences of human alpha-synuclein overexpression in the primate ventral midbrain.
Eslamboli, A; Romero-Ramos, M; Burger, C; Bjorklund, T; Muzyczka, N; Mandel, RJ; Baker, H; Ridley, RM; Kirik, D
Brain : a journal of neurology  130  799-815  2007

Kivonat megmutatása
17303591 17303591
Aggresome-related biogenesis of Lewy bodies.
Kevin St P McNaught, P Shashidharan, Daniel P Perl, Peter Jenner, C Warren Olanow
The European journal of neuroscience  16  2136-48  2002

Kivonat megmutatása
12473081 12473081
Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct.
K A Conway, J C Rochet, R M Bieganski, P T Lansbury
Science (New York, N.Y.)  294  1346-9  2001

Kivonat megmutatása
11701929 11701929

Kapcsolódó termékek és alkalmazások

Related Products

Kategóriák

Life Science Research > Antibodies and Assays > Primary Antibodies